本帖最后由 老马 于 2012-1-13 21:20 编辑 3 y+ o0 H7 K# s% F4 Q3 Z t" _
]# @' y4 ~! j3 C c
爱必妥和阿瓦斯丁的比较
9 L- S' ]9 p' c4 `, c
2 {! M5 H* T4 U8 j" H
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- z6 i0 i* E: M( v4 A; v
% K% G0 u7 r% p3 _, a
$ I Q* G5 \% g
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/+ s+ u! @- _. b3 X M+ @
==================================================
9 b! R* W. \3 L/ K9 u, Q/ y. [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ V) A+ ~% ~5 t( ?0 T2 ^+ [
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& o0 y# A" D- v% V5 j
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( f8 r8 R0 J. S$ m
|
显身卡
